The 12th edition of "Sleisenger and Fordtran's Gastrointestinal and Liver Disease" is more than just an updated book; it is an investment in clinical excellence. With its new editorial leadership, comprehensive updates, and a powerful digital ecosystem, it continues to set the standard as the "gold standard" reference in the field. It remains the one resource every gastroenterologist and GI professional should have at their fingertips.
: Dedicated sections on the gastrointestinal and hepatic manifestations of , as well as enterocolitis and hepatitis induced by cancer immunotherapy Advanced Technology : Updated insights into the use of AI in endoscopy for improved detection of GI cancers. Visual and Practical Aids : Over 1,100 full-color illustrations and more than 20 procedural videos
Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 12th Edition remains an essential resource across multiple tiers of medical practice:
The 12th edition is available for pre-order at several retailers: Elsevier Health : Offers the Complete 2-Volume Set for approximately ₹31,844 : Lists the hardcover 2-volume set at for ₹20,750. Specialized Medical Bookstores : Retailers like Naresh Book Store (₹20,485) and (₹20,999 ) offer pre-publication pricing. US Elsevier Health digital eBook access included with this edition? s gastrointestinal and liver disease 12th edition
for achalasia and spastic esophageal disorders.
The 12th edition introduces vital structural overhauls and content updates designed to mirror the current landscape of digestive health.
Serves as the ultimate reference for complex cases, rare diseases, and validating therapeutic protocols. : Dedicated sections on the gastrointestinal and hepatic
The 12th edition of Sleisenger and Fordtran's Gastrointestinal and Liver Disease provides several benefits to healthcare professionals, including:
The 12th edition of "S. Gastrointestinal and Liver Disease" includes several notable updates and highlights:
| | Key Update in the 12th Edition | | :--- | :--- | | Eosinophilic Esophagitis (EoE) | Updated diagnostic criteria (EoE Histology Scoring System); new therapies including budesonide oral suspension and dupilumab. | | Inflammatory Bowel Disease (IBD) | Comparative efficacy of advanced therapies (JAK inhibitors, anti-IL23, S1P modulators); role of intestinal ultrasound for monitoring. | | Pancreatic Cystic Lesions | Revised Sendai and Fukuoka guidelines; role of molecular markers (KRAS/GNAS mutations) in cyst fluid. | | Celiac Disease | Novel serologic markers (deamidated gliadin peptides); management of non-responsive celiac disease; potential for lanrazenotide. | | Colorectal Cancer Screening | USPSTF updated age to 45; role of multitarget stool DNA (Cologuard) and blood-based tests (Shield); post-polypectomy surveillance intervals. | US Elsevier Health digital eBook access included with
The 12th edition is guided by a fresh editorial team that brings contemporary expertise and vision:
This reference is designed for the entire multidisciplinary GI care team, including:
Irritable Bowel Syndrome (IBS) and motility disorders. Liver and Pancreatic Disorders
To address entirely new clinical challenges, the 12th edition introduces several important new chapters and sections: